CJC-1295 + Ipamorelin (NO-DAC)

$90.00

A complementary combination of two growth hormone–related research peptides that act through distinct receptor pathways. Commonly studied together for their synergistic signaling effects and coordinated influence on pulse dynamics in preclinical models. For research purposes only. Not for human consumption.

Category:
Tags:

CJC-1295 No DAC (Modified GRF 1-29) and Ipamorelin represent a complementary pairing of two distinct growth hormone secretagogues. CJC-1295 No DAC functions as a GHRH analog, interacting with growth hormone–releasing hormone pathways, while Ipamorelin is a selective GHRP that targets the ghrelin receptor (GHS-R1a).

These compounds are often studied together due to their activity on separate receptor systems involved in growth hormone signaling. Research suggests that GHRH analogs primarily influence signal amplitude, while GHRPs are associated with modulation of signaling frequency and timing. When evaluated in combination, these mechanisms have demonstrated synergistic effects in preclinical models, producing responses beyond those observed with either compound alone.

This pairing reflects the multi-pathway nature of growth hormone regulation, where coordinated signaling contributes to pulsatile release patterns.

For research purposes only. Not for human consumption.

Related Products

Research Access Notice

I acknowledge that I am a qualified researcher or institutional professional and that any products purchased are intended solely for lawful research purposes. These materials are not for human or animal use, nor for clinical, diagnostic, or therapeutic applications. I accept full responsibility for ensuring compliance with all applicable laws and regulations, assume all risks associated with the handling and use of these materials, and agree to release the company from any liability or claims arising from their use.

Due to regulatory changes in this industry, an account login is now required to view product information and continue browsing. To complete access, users must verify that they are 21 or older and confirm both their email address and phone number.